Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 14Myeloid 8Sarcoma 1NET 1Lymphoid 1Endocrine 1Classical hematology 1CNS 1Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Hodgkin Disease 1

Interventions

Cyclophosphamide 170Rituximab 143Specimen Handling 82venetoclax 79fludarabine 79obinutuzumab 67Vincristine 67Doxorubicin 65Biopsy 64Prednisone 63Magnetic Resonance Spectroscopy 63zanubrutinib 52Lenalidomide 52Dexamethasone 48Cytarabine 43Methotrexate 42blinatumomab 40Immunotherapy, Adoptive 38acalabrutinib 37Bendamustine Hydrochloride 37Etoposide 32fludarabine phosphate 31ibrutinib 28glofitamab 28polatuzumab vedotin 26pirtobrutinib 24orelabrutinib 24Gemcitabine 23Injections 21pembrolizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × decitabine and cedazuridine drug combination × Lymphoid × Clear all
NCT05272384 2026-05-13

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Recruiting
32 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡